Conditions: Macular Degeneration
Keywords: Age-related Macular Degeneration
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.

Detailed description:
MD7114987 is a Phase 2a study designed to determine whether pazopanib eye drops have the potential to reduce retinal edema and maintain or improve visual acuity in persons with a previously untreated subfoveal choroidal neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD) and to further characterize the safety and tolerability of pazopanib eye drops administered over a 12-week period.

Arms:
arm 1: pazopanib topical ocular administration

Interventions: intervention 1: pazopanib eye drops
Intervention descriptions: intervention 1: 10 mg/mL (1 drop) four times daily

Protocol document: